Key result
Ivabradine improves LV diastolic function and cuts HF mortality, but prognostic value in HR>70 bpm remains uninvestigated.
Why the study?
The prognostic significance of ivabradine in patients with CHF with preserved LVEF of ischemic genesis and heart rate over 70 beats/min receiving maximum tolerated doses of beta-blockers remains not fully investigated.
Answers are grounded in this paper and cite their sources.
The abstract highlights a knowledge gap regarding the prognostic significance of ivabradine in patients with ischemic heart failure with preserved ejection fraction and heart rate >70 beats/min receiving maximum tolerated beta-blockers.
Ischemic heart disease (IHD) and chronic heart failure (CHF) belong to leading causes of death among patients with cardiovascular diseases (CVD). Modern medical approaches to the treatment of patients with CHF do not always provide a significant improvement in the quality of life, a decrease in the frequency of CHF exacerbations and hospitalizations, and an improvement of the long-term prognosis. According to the neurohumoral theory of IHD and CHF development, the blockade of the sympathoadrenal system with β-adrenoblockers (β-AB) is pathogenetically substantiated, and preparations of this group are recommended as one of the main classes of drugs for the treatment of patients with CHF. However, selection of heart rhythm slowing therapy in patients with CHF of ischemic genesis is often difficult due to the development of undesirable side effects of β-AB, intolerance and/or due to the presence of contraindications for their use. Randomized studies have shown that prescribing a combination of β-AB and If-channel blocker ivabradine for heart rate (HR) reduction or solely ivabradine when use of β-AB is impossible in complex CHF therapy, improves the left ventricle (LV) diastolic function, reducing mortality from CHF decompensation. However, the prognostic significance of the use of ivabradine in patients with CHF with preserved left ventricular ejection fraction of ischemic genesis with heart rate higher than 70 beats/min receiving maximum tolerated doses of β-AB remains not fully investigated.
No takes yet. Share an insight, caveat, or question.
Belenkov et al. (2019) conducted a review in Ischemic heart disease and chronic heart failure. Ivabradine was evaluated. Ivabradine improves left ventricular diastolic function and reduces mortality from heart failure decompensation, but its prognostic value in patients with heart rate >70 beats/min remains uninvestigated.
Synapse has enriched 10 related papers. Consider them for comparative context: